和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02256 和誉-B

休市中 09-25 16:08:14

8.960

-0.060

-0.67%

最高9.300	最低8.720	成交量72.50万
今开8.995	昨收9.020	日振幅6.43%
总市值64.24亿	流通市值64.24亿	总股本7.17亿
成交额642.91万	换手率0.10%	流通股本7.17亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02256","market":"HK","secType":"STK","nameCN":"和誉-B","latestPrice":8.96,"timestamp":1790323694004,"preClose":9.02,"halted":0,"volume":725000,"delay":0,"changeRate":-0.006651884700665047,"floatShares":717000000,"shares":717000000,"eps":0.088442,"marketStatus":"休市中","change":-0.06,"latestTime":"09-25 16:08:14","open":8.995,"high":9.3,"low":8.72,"amount":6429105,"amplitude":0.064302,"askPrice":8.96,"askSize":1000,"bidPrice":8.9,"bidSize":10000,"shortable":3,"etf":0,"ttmEps":-0.749,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790559000000},"marketStatusCode":7,"adr":0,"listingDate":1634054400000,"exchange":"SEHK","adjPreClose":9.02,"openAndCloseTimeList":[[1790299800000,1790308800000],[1790312400000,1790323200000]],"volumeRatio":0.5220938599156877,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02256","defaultTab":"news","newsList":[{"id":"2670144059","title":"和誉-B(02256)9月25日斥资44.46万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2670144059","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670144059?lang=zh_cn&edition=full","pubTime":"2026-09-25 20:42","pubTimestamp":1790340177,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年9月25日，该公司斥资44.46万港元回购5万股股份，每股回购价8.855-8.915港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","BK1161","LU2778985437.USD","LU2476274308.USD","LU2488822045.USD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU2476274720.SGD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132444498","title":"和誉-B回购5万股股份，涉资约44.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1132444498","media":"公告速递","labels":["shareholding","SGX"],"top":1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132444498?lang=zh_cn&edition=full","pubTime":"2026-09-25 20:41","pubTimestamp":1790340089,"startTime":"0","endTime":"0","summary":"和誉-B于2026年9月25日发布翌日披露公告，披露当日于香港联交所场内回购普通股5万股，占此前已发行股本的约0.00697%。本次回购价格区间介于每股港币8.855元至8.915元，合计耗资约44.46万港元。回购后，公司已发行股本降至716,887,350股，库藏股增加至9,318,000股，总股份数为726,205,350股。公告显示，和誉-B回购授权决议于2026年5月20日获通过，授权总股数为71,646,135股。公司确认已遵守香港联交所证券上市规则及相关法律法规的要求。本公告由联席公司秘书张菡兮签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B回购5万股股份，涉资约44.46万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187392222","title":"和誉-B于9月24日回购8万股股份，总额约71.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187392222","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1187392222?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:16","pubTimestamp":1790248619,"startTime":"0","endTime":"0","summary":"和誉-B于2026年9月24日公告，公司在香港联交所场内回购普通股80,000股，占回购前已发行股本的约0.01116%。回购价格介乎每股8.89港元至9.035港元，合计支付价格约719,400港元。公告显示，和誉-B于2026年5月20日通过购回授权，获准回购股份总数为71,646,135股，截至回购授权通过当日，公司已在包括香港联交所在内的证券交易所合计回购1,524,000股，占当日已发行股本的约0.21271%。公司确认，本次回购已获得董事会正式批准，并遵守香港联交所证券上市规则以及相关法律法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B于9月24日回购8万股股份，总额约71.94万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246227","title":"和誉-B(02256.HK)9月24日斥资71.94万港元回购8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246227","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669246227?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:14","pubTimestamp":1790248475,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2476274308.USD","IE00B543WZ88.USD","LU2476274720.SGD","LU2778985437.USD","LU2488822045.USD","BK1161","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669517476","title":"招商证券国际：维持和誉-B(02256.HK)目标价32.5港元及“增持”评级 认为公司被市场显著低估","url":"https://stock-news.laohu8.com/highlight/detail?id=2669517476","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669517476?lang=zh_cn&edition=full","pubTime":"2026-09-23 11:43","pubTimestamp":1790135009,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2476274308.USD","02256","IE00B543WZ88.USD","BK1161","LU2488822045.USD","BK1564","06099","IE00BPRC5H50.USD","IE00B5MMRT66.SGD","LU2778985437.USD","BK1147","LU2476274720.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104123032","title":"和誉-B 2026年中期营收0.97亿元，经调整净亏损1.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104123032","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104123032?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:39","pubTimestamp":1790066369,"startTime":"0","endTime":"0","summary":"本季度信息\n2026年上半年，和誉-B实现营收0.97亿元，同比下降84%。毛利约0.96亿元，同比下降84%。经调整净亏损1.42亿元，同比下降142%。经营活动现金流从上年同期的3.03亿元减少至-2.21亿元。\n成本方面，研发开支约2.46亿元，同比增长8%，在营收中的占比达253%。行政开支约4,660万元，同比增长31.6%。\n业务分项\n报告期内，收入主要来自公司核心产品CSF-1R抑制剂贝捷迈在中国首张处方销售所触发的里程碑付款及销售分成。\n高管解读\n（无相关高管原话披露）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B 2026年中期营收0.97亿元，经调整净亏损1.42亿元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669713703","title":"港股异动 | 和誉-B(02256)盘中涨近8% ABSK061 II期临床研究获得积极初步疗效结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669713703","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669713703?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:56","pubTimestamp":1789970165,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和誉-B盘中涨近8%。截至发稿，涨7.05%，报8.88港元，成交额1042.56万港元。消息面上，和誉发布公告称，公司附属公司和誉医药的选择性口服小分子FGFR2/3抑制剂lavengratinib治疗儿童软骨发育不全的II期临床研究获得积极初步疗效结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02256","LU2476274720.SGD","LU2778985437.USD","BK1161","LU2476274308.USD","LU2488822045.USD","VXUS","IE00B543WZ88.USD","BK4585","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","BK4588","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105953034","title":"和誉-B公布Lavengratinib（Absk061）治疗软骨发育不全的II期初步积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1105953034","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105953034?lang=zh_cn&edition=full","pubTime":"2026-09-21 09:06","pubTimestamp":1789952798,"startTime":"0","endTime":"0","summary":"和誉-B（ABBISKO-B）今日宣布，其候选药物Lavengratinib（Absk061）在针对软骨发育不全的II期临床试验中取得了初步的积极成果。这一消息为该公司在罕见病治疗领域的布局注入了新的动力。此次公布的二期数据，不仅展示了该药物在改善患者症状方面的潜力，也为其后续的临床开发奠定了坚实的基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2476274720.SGD","LU2476274308.USD","IE00BPRC5H50.USD","LU2488822045.USD","02256","LU2778985437.USD","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669133106","title":"和誉-B(02256.HK)：和誉医药公布Lavengratinib (ABSK061)治疗软骨发育不全II期临床研究积极初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2669133106","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669133106?lang=zh_cn&edition=full","pubTime":"2026-09-21 08:17","pubTimestamp":1789949821,"startTime":"0","endTime":"0","summary":"格隆汇9月21日丨和誉-B发布公告，公司的附属公司上海和誉生物医药科技有限公司宣布，其选择性口服小分子FGFR2/3抑制剂lavengratinib治疗儿童软骨发育不全的II期临床研究获得积极初步疗效结果。在初始且最低剂量组中，6岁及以上ACH儿童接受lavengratinib治疗27周后，年化身高增长速度较基线平均增加+2.4 cm╱年，应答率达到100%。Lavengratinib整体耐受性良好，未观察到与FGFR1或FGFR2相关的不良事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260921/32375901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["09939","LU2476274720.SGD","LU2488822045.USD","159938","LU2778985437.USD","BK1515","IE00B5MMRT66.SGD","IE00B543WZ88.USD","LU2476274308.USD","BK1574","02256","BK1161","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190577329","title":"和誉-B（02256）披露lavengratinib治疗软骨发育不全II期试验取得积极初步疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1190577329","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190577329?lang=zh_cn&edition=full","pubTime":"2026-09-21 08:11","pubTimestamp":1789949518,"startTime":"0","endTime":"0","summary":"2026年9月21日，和誉-B（02256）发布自愿性公告，旗下全资子公司上海和誉生物医药科技有限公司正在开展的口服小分子FGFR2/3抑制剂lavengratinib（ABSK061）用于儿童软骨发育不全（Achondroplasia，ACH）的II期临床研究获得积极初步结果。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196203310","title":"和誉-B回购7.90万股股份，总涉资约66.67万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196203310","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196203310?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:32","pubTimestamp":1789727528,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年9月18日公告，披露在香港联交所场内回购7.90万股普通股，占当日现有已发行股本约0.01102%。本次回购价格区间为每股港币8.375元至8.525元，合计支付约港币66.67万元。回购完成后，公司已发行股本由7.17096350亿股降至7.17017350亿股，库藏股数增加至918.8万股，合并计算公司的已发行股份总数维持在7.26205350亿股。公司于2026年5月20日获通过回购授权，回购总额度为7164.6135万股。此外，根据公告，下一次新发行股份或转让库藏股的暂止期至2026年10月18日。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B回购7.90万股股份，总涉资约66.67万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175668999","title":"和誉-B（02256）特别股东大会通过更名议案，416,227,695股全票赞成","url":"https://stock-news.laohu8.com/highlight/detail?id=1175668999","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175668999?lang=zh_cn&edition=full","pubTime":"2026-09-17 21:41","pubTimestamp":1789652475,"startTime":"0","endTime":"0","summary":"2026年9月17日，和誉-B在香港召开股东特别大会，就更改公司名称的特别决议案进行表决。根据公司随后披露的投票结果，出席会议并具有投票权的股东合计投出416,227,695股赞成票，占有效投票股份的100.0000%；反对票为0股，占比0.0000%。上述决议案已获正式通过。扣除上述股份后，本次股东大会具备投票权的股份总数为668,267,335股。会议由公司执行董事兼董事会主席徐耀昌博士主持。香港中央证券登记有限公司受委任为本次会议的监票人。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146763338","title":"和誉-B：9月17日回购2万股，耗资约16.75万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1146763338","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146763338?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:11","pubTimestamp":1789643460,"startTime":"0","endTime":"0","summary":"和誉-B于2026年9月17日发布翌日披露报表，公告显示，公司于2026年9月17日在香港联交所场内回购2万股普通股，占当日回购前公司已发行股本约0.00279%。回购价格每股介乎港币8.25元至8.52元，合计耗资约16.75万港元。经此次回购后，公司已发行股本减少至717,096,350股，库藏股数量增至9,109,000股，公司股本总数为726,205,350股。在本次回购后，公司预计将有一段暂止期，在此期间公司不得发行新股或转让库藏股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B：9月17日回购2万股，耗资约16.75万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668969407","title":"和誉-B(02256)9月17日斥资16.75万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668969407","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668969407?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:08","pubTimestamp":1789643297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年9月17日斥资16.75万港元回购2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497527.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02256","LU2476274308.USD","LU2476274720.SGD","IE00BPRC5H50.USD","LU2488822045.USD","IE00B5MMRT66.SGD","LU2778985437.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197778262","title":"和誉-B 2026年9月16日回购6.5万股股份，耗资约54.66万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197778262","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197778262?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:07","pubTimestamp":1789556836,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年9月16日发布翌日披露报表，公告公司当日通过香港联交所场内回购普通股65,000股，约占此前已发行股本的0.00906%。回购价格区间介于每股8.22港元至8.80港元，合计耗资约54.66万港元。公司购回授权决议于2026年5月20日获得通过，可回购股份总数为71,646,135股。公司在公告中表示，所有购回行为已获得董事会正式授权并遵循香港联交所上市规则及相关法律法规的规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B 2026年9月16日回购6.5万股股份，耗资约54.66万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138133400","title":"和誉-B：9月15日回购5万股股份，总金额约42.72万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138133400","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138133400?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:31","pubTimestamp":1789471918,"startTime":"0","endTime":"0","summary":"和誉-B于2026年9月15日发布翌日披露报表，披露公司当日在香港联交所场内回购普通股5万股，约占回购前公司已发行股本的0.00697%。本次回购每股价格介乎每股港币8.465元至8.705元，合计涉资约42.72万港元。回购完成后，公司已发行股份总数维持在7.2620535亿股，其中流通股数减至7.1718135亿股，库存股份增加至902.4万股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B：9月15日回购5万股股份，总金额约42.72万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667412326","title":"和誉-B(02256)9月15日斥资42.7万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667412326","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667412326?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:26","pubTimestamp":1789471614,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，于2026年9月15日斥资42.7万港元回购5万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496405.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274720.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU2476274308.USD","IE00BPRC5H50.USD","LU2488822045.USD","02256","LU2778985437.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108322242","title":"和誉-B回购6万股股份，总额约51.44万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1108322242","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108322242?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:16","pubTimestamp":1789380995,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年9月14日发布翌日披露报表，公告当日在香港联交所场内回购股份6万股，占回购前公司已发行股本约0.00836%。最高回购价为每股港币8.685元，最低回购价为每股港币8.335元，合计支付约51.44万港元。上述回购基于公司于2026年5月20日通过的购回授权，该授权总额为71,646,135股。公告显示，和誉-B确认已遵循香港联交所证券上市规则及相关法律法规，履行了所有适用的审批及披露程序。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"和誉-B回购6万股股份，总额约51.44万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657613","title":"和誉-B(02256)9月14日耗资约51.44万港元回购6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657613","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667657613?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:13","pubTimestamp":1789380806,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)公布，2026年9月14日耗资约51.44万港元回购6万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495731.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","BK1161","IE00B5MMRT66.SGD","LU2476274720.SGD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU2778985437.USD","02256"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156098303","title":"和誉-B(02256)于9月11日回购5万股股份 总涉资约41.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156098303","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156098303?lang=zh_cn&edition=full","pubTime":"2026-09-11 18:47","pubTimestamp":1789123645,"startTime":"0","endTime":"0","summary":"和誉开曼有限责任公司于2026年9月11日公告，当日于香港联交所场内回购普通股50,000股，占当日前已发行股份总数约0.00697%。每股购回价介乎8.095港元至8.475港元，平均价格为8.2603港元，总涉资约41.30万港元。完成后，公司已发行股份数量由717,341,350股降至717,291,350股，库藏股数增至8,914,000股，合计股本总数仍为726,205,350股。公司确认，上述回购已获得董事会正式授权并遵守了香港联交所证券上市规则及相关法律法规的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"和誉-B(02256)于9月11日回购5万股股份 总涉资约41.30万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02256"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbisko.com","stockEarnings":[{"period":"1week","weight":0.0802},{"period":"1month","weight":-0.081},{"period":"3month","weight":-0.0427},{"period":"6month","weight":-0.2803},{"period":"1year","weight":-0.48},{"period":"ytd","weight":-0.3113}],"compareEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.0446},{"period":"3month","weight":0.0811},{"period":"6month","weight":-0.0177},{"period":"1year","weight":-0.0746},{"period":"ytd","weight":-0.0437}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"和誉开曼有限责任公司是一家临床阶段生物制药公司。该公司致力于发现和开发创新差异化的小分子肿瘤疗法。该公司拥有两款核心候选产品ABSK011和 ABSK091，以及12款其他在研产品。ABSK011是一种强效且高选择性的成纤维细胞生长因子受体4(FGFR4) 小分子抑制剂。ABSK091 是一种分子靶向候选产品，也是 FGFR亚型 1、2和3的强效和选择性抑制剂。该公司的产品主要用于肝细胞癌(HCC)、尿路上皮癌(UC) 和胃癌(GC)。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.122249},{"month":2,"riseRate":0.8,"avgChangeRate":0.040621},{"month":3,"riseRate":0.4,"avgChangeRate":0.033777},{"month":4,"riseRate":0.4,"avgChangeRate":0.005698},{"month":5,"riseRate":0.2,"avgChangeRate":-0.025571},{"month":6,"riseRate":0.6,"avgChangeRate":0.025986},{"month":7,"riseRate":0.6,"avgChangeRate":0.025539},{"month":8,"riseRate":0.4,"avgChangeRate":0.067354},{"month":9,"riseRate":0.8,"avgChangeRate":0.036764},{"month":10,"riseRate":0.5,"avgChangeRate":-0.043137},{"month":11,"riseRate":0.6,"avgChangeRate":0.159978},{"month":12,"riseRate":0,"avgChangeRate":-0.092694}],"exchange":"SEHK","name":"和誉-B","nameEN":"ABBISKO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"和誉-B,02256,和誉-B股票,和誉-B股票老虎,和誉-B股票老虎国际,和誉-B行情,和誉-B股票行情,和誉-B股价,和誉-B股市,和誉-B股票价格,和誉-B股票交易,和誉-B股票购买,和誉-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"和誉-B(02256)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供和誉-B(02256)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}